| Identification | Back Directory | [Name]
Iruplinalkib | [CAS]
1854943-32-0 | [Synonyms]
Iruplinalkib
lruplinalkib
2,4-Pyrimidinediamine, 5-chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-(9-methyl-3,9-diazaspiro[5.5]undec-3-yl)phenyl]- | [Molecular Formula]
C29H38ClN6O2P | [MOL File]
1854943-32-0.mol | [Molecular Weight]
569.08 |
| Chemical Properties | Back Directory | [Boiling point ]
769.1±70.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
10.12±0.20(Predicted) | [color ]
Off-white to light yellow | [InChIKey]
ZPCCNHQDFZCULN-UHFFFAOYSA-N | [SMILES]
C1(NC2=CC=C(N3CCC4(CCN(C)CC4)CC3)C=C2OC)=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1 |
| Hazard Information | Back Directory | [Uses]
Iruplinalkib (WX-0593) is an orally active and selective ALK/ROS1 inhibitor. Iruplinalkib can effectively inhibit tyrosine autophosphorylation of ALK and mutant ALK, EGFR, with the IC50 between 5.38 and 16.74 nM. Iruplinalkib is also a suppressive agent of the transporter MATE1, MATE2K, P-gp and BCRP. Iruplinalkib can be used in the study of non-small cell lung cancer[1][2]. | [in vivo]
Iruplinalkib (2.5-10 mg/kg; Oral administration; 3 weeks) has antitumor effect in mouse model of non-small cell lung cancer[1] | Animal Model: | EML4-ALK transfected NCI-H3122 treated female BALB/c nude mice (4-6 weeks old)[1] | | Dosage: | 2.5, 5 and 10 mg/kg | | Administration: | Oral administration (p.o.); 3 weeks | | Result: | Inhibited tumor growth.
Had inhibitory effects on the phosphorylation of ALK, AKT and ERK.
Decreased the levels of phosphorylation of STAT3 and STAT5.
Had no effect on the body weight. |
| [References]
[1] Yang Y, et al. Iruplinalkib (WX 0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. Invest New Drugs. 2023 Apr;41(2):254-266. DOI:10.1007/s10637-023-01350-x
[2] Shi Y, et al. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022;7(1):25. DOI:10.1038/s41392-021-00841-8 |
|
| Company Name: |
RuiKeXin Gold
|
| Tel: |
19938953786 |
| Website: |
ahreaction.com/ |
|